Introduction {#tca12427-sec-0005}
============

At present, surgery continues to be the major component of curative treatment for patients with operable thoracic esophageal cancer.[1](#tca12427-bib-0001){ref-type="ref"} Patients who undergo surgery alone have a median survival rate of 13.6--15.2 months, a two‐year survival rate of 34--37%,[2](#tca12427-bib-0002){ref-type="ref"}, [3](#tca12427-bib-0003){ref-type="ref"} and a 25--42% rate of locoregional failure.[4](#tca12427-bib-0004){ref-type="ref"}, [5](#tca12427-bib-0005){ref-type="ref"} The use of definitive concurrent chemoradiation has a median survival time of 12.5--22 months[6](#tca12427-bib-0006){ref-type="ref"}, [7](#tca12427-bib-0007){ref-type="ref"}, [8](#tca12427-bib-0008){ref-type="ref"}, [9](#tca12427-bib-0009){ref-type="ref"} and five‐year overall survival (OS) of 26%, but 46% of the patients experienced failure within the radiation (RT) field or had persistent disease.[10](#tca12427-bib-0010){ref-type="ref"}

A recent meta‐analysis showed that preoperative chemoradiation followed by surgery, that is, trimodality treatment, significantly improved the rates of pathological complete response (pCR), R0 resection, and OS in patients with esophageal squamous cell carcinoma over surgery alone.[11](#tca12427-bib-0011){ref-type="ref"} However, compared with definitive concurrent chemoradiation in randomized controlled trials, trimodality treatment did not improve OS.[12](#tca12427-bib-0012){ref-type="ref"}, [13](#tca12427-bib-0013){ref-type="ref"} Of note is that these two trials used higher than standard RT doses in the control arm. The current standard RT dose is 40--50 Gy given in 15--25 fractions over three to five weeks.[10](#tca12427-bib-0010){ref-type="ref"}, [14](#tca12427-bib-0014){ref-type="ref"}, [15](#tca12427-bib-0015){ref-type="ref"} These results changed the use of definitive concurrent chemoradiation, which is reserved for cervical esophageal cancer, patients who decline surgery, and inoperable or unresectable tumors.

Over the past 15 years, RT delivery technology methods have improved. A few radiation dosimetric studies have explored the use of the new technology, intensity modulated radiation therapy (IMRT), which can maintain the therapeutic ratio by giving a high RT dose to the tumor while minimizing the dose to the surrounding organs.[16](#tca12427-bib-0016){ref-type="ref"}, [17](#tca12427-bib-0017){ref-type="ref"}, [18](#tca12427-bib-0018){ref-type="ref"} However, these results need to be confirmed in a real clinical setting. Studies have reported fewer postoperative morbidities and higher OS benefit using IMRT.[19](#tca12427-bib-0019){ref-type="ref"}, [20](#tca12427-bib-0020){ref-type="ref"}, [21](#tca12427-bib-0021){ref-type="ref"}, [22](#tca12427-bib-0022){ref-type="ref"} Data regarding high dose chemoradiation using IMRT followed by surgery is sparse. This retrospective study aimed to determine the pathological response rate, OS, progression‐free survival (PFS), locoregional control (LRC), and toxicities of high dose preoperative RT concurrently with chemotherapy and followed by esophagectomy among patients with esophageal squamous cell carcinoma. Potential prognostic factors associated with OS, particularly doses of less than or more than 60 Gy, were also evaluated.

Methods {#tca12427-sec-0006}
=======

Patients {#tca12427-sec-0007}
--------

Before commencement, a multidisciplinary gastrointestinal tumor board discussed all treatment options. Patients with cT2--cT4 or node positive thoracic esophageal cancer who were initially deemed unresectable or marginally resectable and received a preoperative RT (dose \> 50 Gy) with platinum‐based chemotherapy followed by esophagectomy, were retrospectively identified. Tumor staging was based on the American Joint Committee on Cancer 2010 seventh edition staging criteria. Contrast computed tomography (CT) of the chest and abdomen, esophagogastroduodenoscopy, bone scintigraphy, and pathological confirmation of squamous cell carcinoma were included in the pretreatment work‐up. Although endoscopic ultrasound and positron emission tomography/CT (PET/CT) are standard procedures recommended in the National Comprehensive Cancer Network guidelines, issues of reimbursement and complete esophageal obstruction in some patients made endoscopic ultrasound and PET/CT optional in our study. All patients underwent jejunostomy before commencing chemoradiation. The Chulalongkorn University Institutional Review Board approved the study (No 296/59). Informed patient consent was obtained.

Treatment {#tca12427-sec-0008}
---------

All patients received preoperative chemotherapy and RT for five to seven weeks. The majority of the patients received cisplatin 80 mg/m^2^ or carboplatin AUC 5 administered on days 1 and 28, and intravenous infusion of 5‐fluorouracil (5‐FU) 1000 mg/m^2^/day on days 1--4 and 28--31.

Radiation techniques included IMRT, volumetric modulated arc therapy (VMAT) or three‐dimensional radiation therapy (3DRT). Megavoltage photon energy of 6 MV or higher was used. All patients underwent a treatment planning intravenous contrast CT simulation. The CT images were then transferred to a commercial planning system for structural delineation. The gross tumor volumes (GTVs) included the primary tumor (GTV‐primary) and involved regional lymph node(s) greater than 1 cm in diameter or node(s) with a necrotic center (GTV‐LN). The clinical target volume of gross lymph node (CTV‐GLN) was equal to GTV‐LN. The 0.5 cm lateral margin and 4 cm longitudinal margin of the GTV‐primary along the esophagus were extended to create the CTV‐low risk (CTV LR‐primary). Superior and inferior longitudinal margins were decreased to 2 cm beyond the GTV‐primary to obtain the CTV‐high risk (CTV HR‐primary). Elective nodal CTVs (CTV LR‐elective LN) encompassed the paratracheal, para‐esophageal, and supraclavicular nodes for the upper esophageal lesion; para‐esophageal nodes for the mid esophageal lesion; and the para‐esophageal, gastrohepatic, and celiac nodes for the distal esophageal lesion. A uniform margin of 1 cm to these CTVs (CTV‐GLN, CTV LR‐primary, CTV HR‐primary, CTV LR‐elective LN) was used to create planning target volumes (PTVs). All PTVs were at least 0.7 cm away from the spinal cord and were initially treated with 50 Gy in 25 fractions. A shrinking field boost of 10--14 Gy in 5--7 fractions was then delivered to the PTV HR‐primary and the PTV‐GLN. Patients were treated five days per week and all fields were treated each day. Dose--volume constraints were used to plan RT: for the spinal cord, maximum dose \<50 Gy was used; for the lungs, V20 (volume of the lungs received 20 Gy) \< 25%, V10 \< 40%, and the mean lung dose \<18 Gy were used; for the liver V30 \< 30%, and median heart dose \<30 Gy were used. Every effort was made to reduce exposure to the lungs, heart, spinal cord, and liver. The aim of RT treatment planning was to deliver an RT dose of up to 64 Gy to the PTV HR‐primary and PTV‐GLN; however, if the dose to normal organs exceeded dose volume constraints, the total doses for both the PTV HR‐primary and PTV‐GLN were reduced until normal tissue dose volume constraints were met. The Eclipse treatment planning system (Eclipse version 7.2.34, Varian, Palo Alto, CA, USA) was used to design RT plans with lung homogeneity corrections. The treatment was delivered by Varian linear accelerator (Varian Medical Systems Inc., Palo Alto, CA, USA) with dynamic 80‐Leaf multileaf collimators. Electronic portal images and cone beam CT were obtained at the start of RT therapy and performed at least once a week thereafter.

Weekly complete blood count and blood chemistry work‐ups were performed during the course of the chemoradiation. Acute and long‐term toxicities were graded according to the Common Terminology Criteria for Adverse Events version 3.0.[23](#tca12427-bib-0023){ref-type="ref"}

After completion of chemoradiation therapy, follow‐up visits for physical examinations were scheduled every four weeks during the first three months. A multidisciplinary tumor board evaluated tumor response and resectability using CT and esophagogastroduodenoscopy at three months after chemoradiation therapy. If a complete response was not observed and the primary tumor did not attach to vital structures, such as the trachea or major vessels, patients were then considered for salvage transthoracic esophagectomy. One pathologist reviewed all pathological specimens. Pathologic stage was defined according to the tumor node metastasis classification. Patients with surgical pathology of esophagectomy and lymph node specimens without any viable residual tumor cells were considered to have achieved a complete response. After surgery, patients were followed for five years, which included physical examination, complete blood count, and blood chemistry at three‐month intervals for three years, then every six months thereafter for up to five years. CT scans of the chest and abdomen were performed every six months or when clinically indicated.

Statistical analysis {#tca12427-sec-0009}
--------------------

The end points of this study were the pathological response rate, OS, PFS, LRC, and toxicities. OS, PFS, and LRC analyses were computed using the Kaplan--Meier method and compared using log--rank statistics. OS was defined as the time period between the initial RT and any cause of death. PFS was defined as the time period since the initial RT of esophageal cancer until disease recurrence, progression, distant metastasis, or death. LRC was defined as the interval between the initial RT and disease recurrence or progression in the tumor bed and/or regional lymph node. A univariate logistic regression model was used to examine the association between clinicopathological factors and OS, LRC, and PFS. Factors with a *P* value of less than 0.25 in the univariate analysis were entered into the Cox proportional hazards regression analysis. SPSS version 17.0 was used for statistical analysis. Because of the large number of factors tested in the univariate analyses and our small patient sample, we used an adjusted *P* value of 0.004 or less as the significant level to prevent the risk of false positive results. Otherwise, a *P* value of 0.05 or less was considered statistically significant.

Results {#tca12427-sec-0010}
=======

From February 2006 to June 2015, 44 patients with squamous cell carcinoma of the thoracic esophagus were treated with high‐dose chemoradiation followed by esophagectomy; 36 (81.8%) were men and the median age was 60 years. Before treatment, most patients had clinical stage III (70.5%) cancer. Baseline PET/CT was carried out in seven patients (16%). Detailed patient characteristics are shown in Table [1](#tca12427-tbl-0001){ref-type="table-wrap"}. Fifty percent of the patients were irradiated with more than 60 Gy. When dividing patients in to two groups (i.e. ≤60 Gy vs. \>60 Gy), there were proportionally more N2, stage IIIB, and tumor length \>8 cm in the ≤60 Gy group. This was explained by the method of RT planning in which the medical physicist had to decrease the total dose to this group of patients to maintain an optimal dose to the surrounding normal tissue. As demonstrated in Table [2](#tca12427-tbl-0002){ref-type="table-wrap"}, normal tissue doses were comparable between both groups. The average volume of bilateral lungs receiving more than 20 Gy (V20) was 24.5%, the mean lung dose was 14 Gy, and the average median heart dose was 29.2 Gy.

###### 

Patient characteristics at baseline

  Characteristics            Radiation dose ≤ 60 Gy   Radiation dose \> 60Gy   All               
  -------------------------- ------------------------ ------------------------ ----- ------ ---- ------
  Gender                                                                                         
  Male                       19                       86.4                     17    77.3   36   81.8
  Female                     3                        13.6                     5     22.7   8    18.2
  Clinical T stage                                                                               
  T2                         1                        4.5                      1     4.5    2    4.5
  T3                         18                       81.8                     18    81.8   36   81.8
  T4                         3                        13.6                     3     13.6   6    13.6
  Clinical N stage                                                                               
  N0                         8                        36.4                     5     22.7   13   29.5
  N1                         6                        27.3                     13    59.1   19   43.2
  N2                         7                        31.8                     2     9.1    9    20.5
  N3                         1                        4.5                      2     9.1    3    6.8
  Clinical stage grouping                                                                        
  IIA                        2                        9.1                      1     4.5    3    6.8
  IIB                        7                        31.8                     4     18.2   10   22.7
  IIIA                       4                        18.2                     13    59.1   18   40.9
  IIIB                       7                        31.8                     1     4.5    8    18.2
  IIIC                       2                        9.1                      3     13.6   5    11.4
  ECOG performance status                                                                        0.0
  0--1                       21                       95.5                     22    100    43   97.7
  2                          1                        4.5                      0     0      1    4.5
  Grading                                                                                        0.0
  Grade 1                    6                        27.3                     7     31.8   13   29.5
  Grade 2                    9                        40.9                     9     40.9   18   40.9
  Grade 3                    1                        4.5                      3     13.6   4    9.1
  Unknown                    6                        27.3                     3     13.6   9    20.5
  Location                                                                                       
  Upper thoracic esophagus   1                        4.5                      1     4.5    2    4.5
  Mid thoracic esophagus     10                       45.5                     11    50     21   47.7
  Lower thoracic esophagus   11                       50                       10    45.5   21   47.7
  Length                                                                                         
  ≤8 cm                      15                       68.2                     17    77.3   32   72.7
  \>8 cm                     7                        31.8                     5     22.7   12   27.3
  Weight loss                                                                                    
  \<10%                      14                       63.6                     14    63.6   28   63.6
  ≥10%                       8                        36.4                     8     36.4   16   36.4

ECOG, Eastern Cooperative Oncology Group.

###### 

Treatment modalities administered to patients

  Treatment parameters     Radiation dose ≤ 60 Gy   Radiation dose \> 60 Gy   All               
  ------------------------ ------------------------ ------------------------- ----- ------ ---- ------
  Chemotherapy regimens                                                                         
  Cisplatin/5FU            11                       50.0                      16    72.7   27   61.4
  Carboplatin/5FU          8                        36.4                      6     27.3   14   31.8
  Other                    3                        13.6                      0     0      3    6.8
  Radiation technique                                                                           
  3D conformal             1                        4.5                       1     4.5    2    4.5
  IMRT                     15                       68.2                      20    90.9   35   79.5
  VMAT                     6                        27.3                      1     4.5    7    15.9
  Average dose                                                                                  
  Mean lung dose (Gy)                               13.8                            14.2        14
  Lung V20 (%)                                      24.4                            24.6        24.5
  Lung V10 (%)                                      49.9                            46.3        48.1
  Median heart dose (Gy)                            28.1                            30.2        29.2
  Resection margin                                                                              
  R0 resection             15                       68.2                      16    72.7   31   70.5
  R1 resection             3                        13.6                      3     13.6   6    13.6
  R2 resection             4                        18.2                      3     13.6   7    15.9
  Pathologic staging                                                                            
  pCR                      8                        36.4                      13    59.1   21   47.7
  Non pCR                  14                       63.6                      9     40.9   23   52.3

5FU, 5‐fluorouracil; IMRT, intensity‐modulated radiotherapy; pCR, pathologic complete response; VMAT, volumetric arc therapy.

V20 volume of the lung receiving 20 Gy; V10 volume of the lung receiving 10 Gy.

Intensity modulated radiation therapy, VMAT, and 3DRT were performed in 35, seven, and two patients, respectively. All patients were scheduled for concomitant chemotherapy. Forty‐one of the 44 patients (93.2%) received concurrent cisplatin or carboplatin plus 5‐FU. Three patients received weekly carboplatin AUC 2 and paclitaxel (50 mg/m^2^). The median time from post‐RT to surgery was four months. Thirty‐one patients (70.5%) underwent R0 resection.

Pathological response, locoregional control, and survival {#tca12427-sec-0011}
---------------------------------------------------------

The median follow‐up duration for the entire cohort was 22.4 months (range 5--121). Twenty‐one patients (47.7%) achieved a pCR. Patients who received \>60 Gy had higher pCR rates than those in the lower dose group (59.1% vs. 36.4%). Median OS was 25.6 months and two‐year OS was 55.9% (Fig [1](#tca12427-fig-0001){ref-type="fig"}). The two‐year OS for those who received RT \>60 Gy and ≤60 Gy doses were 73% and 35%, respectively (*P* = 0.026) (Fig [2](#tca12427-fig-0002){ref-type="fig"}). Two‐year PFS was 28.6% (Fig [3](#tca12427-fig-0003){ref-type="fig"}). Median PFS was 16.2 months. Locoregional recurrence was observed in 19 patients (43.2%), which translated into an estimated two‐year LRC of 56%. Seventeen patients (38.6%) developed distant failure. The most common metastatic sites were the lungs 13.6%, non‐regional nodal metastases 13.6%, and the liver 4.5%. To date, 32 patients have died during the follow‐up period. Of these patients, 31 died as a result of cancer recurrence and one patient developed pneumonia and sepsis after esophagectomy.

![Overall survival curve.](TCA-8-219-g002){#tca12427-fig-0001}

![Overall survival curve stratified by radiation dose.](TCA-8-219-g001){#tca12427-fig-0002}

![Progression‐free survival curve.](TCA-8-219-g004){#tca12427-fig-0003}

Univariate analysis {#tca12427-sec-0012}
-------------------

Multiple variables including age, gender, clinical stage, grading, location, length of tumor, weight loss, PTV dose, resection margin status, and pathological staging were selected for univariate analysis. Only resection margin status was significantly associated with two‐year OS. The two‐year OS in patients who underwent R0 resection was 71% compared with 21% who had R1--2 resection (*P* = 0.002). Patients who achieved pCR had a favorable two‐year PFS (50% vs. 13%; *P* = 0.002) compared with the non pCR group. Details of the univariate analysis are shown in Table [3](#tca12427-tbl-0003){ref-type="table-wrap"}.

###### 

Univariate analysis of OS, LRC, and PFS

                            N    Two‐year OS   SD   *P*                                             Two‐year LRC   SD   *P*     Two‐year PFS   SD   *P*
  ------------------------- ---- ------------- ---- ----------------------------------------------- -------------- ---- ------- -------------- ---- -----------------------------------------------
  Gender                                                                                                                                            
  Male                      36   56            9    0.123                                           52             9    0.387   28             8    0.635
  Female                    8    57            19                                                   75             15           31             18   
  Age                                                                                                                                               
  \<60                      24   67            10   0.085                                           58             11   0.896   34             11   0.402
  ≥60                       20   43            11                                                   54             11           23             10   
  Clinical T stage                                                                                                                                  
  T2/T3                     38   51            9    0.334                                           57             8    0.975   28             8    0.900
  T4                        6    67            20                                                   50             20           33             19   
  Clinical N stage                                                                                                                                  
  N0                        13   63            15   0.693                                           75             13   0.161   57             15   0.118
  N+                        31   53            9                                                    49             9            18             7    
  Clinical stage grouping                                                                                                                           
  II                        13   54            15   0.754                                           49             15   0.413   40             15   0.608
  III                       31   56            9                                                    60             9            25             8    
  Grading                                                                                                                                           
  Grade 1                   13   59            14   0.093                                           73             14   0.292   48             16   0.176
  Grade 2                   18   50            13                                                   45             12           13             9    
  Grade 3                   4    75            22                                                   50             25           50             25   
  Unknown                   9    56            17                                                   56             17           22             14   
  Location                                                                                                                                          
  Upper/mid                 23   61            10   0.902                                           52             11   0.581   34             10   0.697
  Lower                     21   51            12                                                   62             12           24             10   
  Length                                                                                                                                            
  ≤8 cm                     32   56            9    0.316                                           53             9    0.657   18             7    0.068
  \>8 cm                    12   56            15                                                   67             14           57             15   
  Weight loss                                                                                                                                       
  \<10%                     28   50            10   0.268                                           51             10   0.543   16             7    0.065
  ≥10%                      16   67            12                                                   66             13           53             13   
  Dose                                                                                                                                              
  \>5000--6000              22   35            12   0.026                                           41             12   0.104   18             10   0.143
  \>6000                    22   73            10                                                   68             10           36             10   
  Resection margin                                                                                                                                  
  R0                        31   71            9    0.002[\*](#tca12427-note-0004){ref-type="fn"}   61             9    0.277   36             9    0.021
  R1--R2                    13   21            12                                                   45             14           10             9    
  Pathologic staging                                                                                                                                
  pCR                       21   71            11   0.055                                           78             10   0.031   50             12   0.002[\*](#tca12427-note-0004){ref-type="fn"}
  non pCR                   23   44            10                                                   39             10           13             7    

Factors with *P* \< 0.004 (adjusted *P* value for multiple comparison).

LRC, locoregional control; OS, overall survival; pCR, pathologic complete response; PFS, progression‐free survival; SD, standard deviation.

Multivariate analysis {#tca12427-sec-0013}
---------------------

Resection margin status and RT dose were significantly related to OS with a hazard ratio (HR) of 0.290 (95% confidence interval \[CI\] 0.135--0.624; *P* = 0.002) and 0.389 (95% CI 0.181--0.839; *P* = 0.016), respectively, in favor of R0 resection (Fig [4](#tca12427-fig-0004){ref-type="fig"}) and \>60 Gy group (Fig [2](#tca12427-fig-0002){ref-type="fig"}). Only pCR was associated with improved LRC (HR 0.342, 95% CI 0.123--0.950; *P* = 0.04) and PFS (HR 0.324, 95% CI 0.152--0.689; *P* = 0.003).

![Overall survival stratified by resection margin.](TCA-8-219-g003){#tca12427-fig-0004}

Toxicities {#tca12427-sec-0014}
----------

Acute toxicities during chemoradiation are listed in Table [4](#tca12427-tbl-0004){ref-type="table-wrap"}. Grade 3--4 acute toxicities occurred in 29 patients (66%). The most common acute grade 3--4 toxicities were dysphagia (63.6%) and neutropenia (25%). Treatment‐related grade 1--2 weight loss was observed in 26 patients (59.1%).

###### 

Acute adverse events during chemoradiation

  Acute toxicities    Grade 1--2   Grade 3--4        
  ------------------- ------------ ------------ ---- ------
  Anemia              20           45.5         2    4.5
  Neutropenia         12           27.3         11   25.0
  Thrombocytopenia    17           38.6         3    6.8
  Dysphagia           3            6.8          28   63.6
  Nausea              5            11.4         1    2.3
  Vomiting            8            18.2         0    0.0
  Cough               4            9.1          0    0.0
  Creatinine rising   0            0.0          0    0.0
  High fever          0            0.0          1    2.3
  Diarrhea            1            2.3          2    4.5
  Fatigue             1            2.3          1    2.3
  Weight loss         26           59.1         2    4.5

The incidence of surgical‐related toxicity was low and well tolerated. There was one postoperative death from pneumonia and sepsis. One patient had grade 4 acute renal failure. Two patients experienced wound infection or anastomotic stricture requiring surgical re‐intervention. Two patients experienced respiratory failure requiring ventilator support and subsequently recovered. Common grade 1--2 complications, such as cardiac arrhythmia (15.9%), high fever (15.9%), wound infection (11.4%), and anastomotic stricture (11.4%), were observed. Details of surgical‐related complications are shown in Table [5](#tca12427-tbl-0005){ref-type="table-wrap"}.

###### 

Post‐operative morbidity and mortality

  Surgically‐related complications   Grade 1--2   Grade 3--5                                              
  ---------------------------------- ------------ ------------ ------------------------------------------ -----
  Pneumonia                          4            9.1          1[†](#tca12427-note-0006){ref-type="fn"}   2.3
  Wound infection                    5            11.4         1                                          2.3
  Anastomosis leakage                3            6.8          0                                          0.0
  Anastomotic stricture              5            11.4         1                                          2.3
  Cardiac arrhythmia                 7            15.9         0                                          0.0
  High fever                         7            15.9         1[†](#tca12427-note-0006){ref-type="fn"}   2.3
  Pleural effusion                   3            6.8          0                                          0.0
  Acute renal failure                3            6.8          1                                          2.3
  Chyle leak                         1            2.3          0                                          0.0
  Respiratory failure                0            0            2                                          4.5

Same patient.

Discussion {#tca12427-sec-0015}
==========

Most patients with thoracic squamous cell carcinoma of the esophagus present in locally advanced stages, especially in Thailand. Patients are usually referred for either palliative RT or curative chemoradiation. For unresectable or potentially resectable cases, chemoradiation is the mainstay treatment. The major problem with chemoradiation treatment is the combination of persistent disease and locoregional failure (50%:50%).[10](#tca12427-bib-0010){ref-type="ref"} It has been postulated that locoregional recurrence can be overcome by using higher doses of RT. However, the INT 0123 trial showed that a high RT dose (64.8 Gy) plus concurrent 5‐FU and cisplatin showed no significant difference in median survival (13.0 vs. 18.1 months) or two‐year survival (31% vs. 40%) compared with the standard dose arm (50 Gy), in which more than half of the patients experienced locoregional failure and persistence of the disease post‐treatment.[24](#tca12427-bib-0024){ref-type="ref"}

The second strategy, preoperative chemoradiation followed by esophagectomy versus chemoradiation alone, was examined in two randomized trials. The results revealed that although there was no significant difference in terms of OS, the trimodality treatment had less locoregional relapses in an FFCD 9102 study (34% vs. 43%)[12](#tca12427-bib-0012){ref-type="ref"} and improved two‐year local control in a German trial (64% vs. 41%), compared with chemoradiation alone.[13](#tca12427-bib-0013){ref-type="ref"} Of note, these two studies used doses higher than 50 Gy in the chemoradiation alone arm and used 3DRT.

On the other hand, the Stanford series demonstrated that preoperative standard dose IMRT (50.4 Gy) followed by surgery in 12 patients had a two‐year LRC of 83% and pCR of 18%.[22](#tca12427-bib-0022){ref-type="ref"} In another study, 232 esophageal cancer patients from a cohort were treated with IMRT or 3DRT concurrently with chemotherapy, and 47% of patients underwent esophagectomy. In multivariable analysis, surgical resection resulted in improved OS (HR 0.444; *P* \< 0.0001), while IMRT was associated with a decrease in grade 3 or higher toxicity.[25](#tca12427-bib-0025){ref-type="ref"} On the contrary, 108 patients treated with preoperative (46%) or definitive IMRT concurrently with chemotherapy yielded a comparable two‐year OS using the trimodality technique (63.7%) versus chemoradiation (52.3%) alone (*P* = 0.2059).[26](#tca12427-bib-0026){ref-type="ref"} Because of these conflicting results, we wondered if combining the two postulates for overcoming locoregional failure and recurrence would work if a new RT methodology, such as IMRT or VMAT, was used. We carefully considered the risk versus benefit of integrating both postulates based on available data at the time of the study design. The aim was to achieve a good tumor response while lowering RT toxicities to nearby organs such as the lungs and heart enough so that, in cases of less than clinical complete remission, surgeons could perform salvage transthoracic esophagectomy and still achieve a lower surgical‐related morbidity and mortality rate.

Our results showed a two‐year OS of 55.9%, which was higher than in the FFCD 9102 (34%) and German trials' (39.9%) trimodality arms. The median survival in this study (25.6 months) was also higher than the data reported by the FFCD 9102 (17.7 months) and the German trial (16.4 months). Our two‐year LRC was 56%, compared with 64--66% reported in the aforementioned trials, and the 46--56% locoregional failure rate in patients treated with definitive chemoradiation in the RTOG 8501 and INT0123 trials.[10](#tca12427-bib-0010){ref-type="ref"}, [12](#tca12427-bib-0012){ref-type="ref"}, [13](#tca12427-bib-0013){ref-type="ref"}, [24](#tca12427-bib-0024){ref-type="ref"} Moreover, the pCR rate in our study was 48%, which was far better than the 22--40% reported by other studies that used an RT dose of \<50 Gy.[13](#tca12427-bib-0013){ref-type="ref"}, [15](#tca12427-bib-0015){ref-type="ref"}, [26](#tca12427-bib-0026){ref-type="ref"}, [27](#tca12427-bib-0027){ref-type="ref"}, [28](#tca12427-bib-0028){ref-type="ref"} Furthermore, our results revealed that patients who received \>60 Gy achieved pCR as high as 59%. pCR had significantly better LRC and PFS in multivariate analysis. This may be because of the use of a higher RT dose, longer intervals (\>3 months) between completion of neoadjuvant chemoradiation and surgery, and more favorable prognostic factors in the \>60 Gy group. We also demonstrated in multivariate analysis that patients who underwent R0 resection and received an RT dose of \>60 Gy had favorable OS outcomes.

Although there has been no randomized trial to support the dose‐response relationship in esophageal cancer, one systematic review showed that the probability of pCR improved with increasing doses of RT.[29](#tca12427-bib-0029){ref-type="ref"} The use of IMRT or VMAT lowered the lung dose and achieved the study\'s pre‐established dose volume constraints of the lungs (V20 = 24.5%, mean lung dose = 14 Gy) and the heart (median dose 29.2 Gy), without exceeding the tolerance levels. This result is comparable to other IMRT or VMAT studies which demonstrated that the lung V20 was between 21% and 25% and the mean heart dose was 21--22 Gy.[18](#tca12427-bib-0018){ref-type="ref"}, [22](#tca12427-bib-0022){ref-type="ref"}, [30](#tca12427-bib-0030){ref-type="ref"} We did not find any difference in terms of survival outcome for patients who received 3DRT versus IMRT/VMAT. However, we recommend that when giving higher than standard RT dose to the PTV while keeping the optimal dose to the surrounding tissue, it is easier to achieve an optimal RT plan using IMRT/VMAT than 3DRT.

Moderate grade toxicities were observed in this study. Grade 3--4 acute toxicities occurred in 66% of the patients, higher than 25--40% found in standard dose IMRT studies.[22](#tca12427-bib-0022){ref-type="ref"}, [25](#tca12427-bib-0025){ref-type="ref"} The most common acute grade 3--4 toxicities were dysphagia (63.6%) and neutropenia (25%). The grade 3--4 dysphagia experienced by our sample was higher than the 42% previously report ed.[13](#tca12427-bib-0013){ref-type="ref"} The higher grade 3--4 dysphagia may be a result of the higher RT dose used in our study. However, all patients in our study had prophylactic jejunostomy to prevent malnutrition. Only 4.5% had grade 3--4 weight loss. The rate of grade 3--4 neutropenia during chemoradiation in this study was comparable or lower than 36% when compared with other reports.[14](#tca12427-bib-0014){ref-type="ref"}, [31](#tca12427-bib-0031){ref-type="ref"}, [32](#tca12427-bib-0032){ref-type="ref"} For example, Roeder *et al.* treated 27 patients with 56 Gy of IMRT, and 26% of the patients experienced grade 3--4 leukopenia.[32](#tca12427-bib-0032){ref-type="ref"} This suggests that the use of high dose IMRT did not significantly alter hematotoxicity, even though IMRT had more monitor units compared with 3DRT. As for the other treatment‐related grade 3 weight loss, only 4.5% was observed in this study, which was lower than the 11% previously reported by Tepper *et al.* [14](#tca12427-bib-0014){ref-type="ref"} This discrepancy may have been a result of the use of prophylactic jejunostomy in this study for every patient before commencing treatment.

Other complications, such as surgical complications, were tolerable. The in‐hospital postoperative mortality rate in our study corroborates data previously reported by other trimodality treatment studies to be 4--11%.[13](#tca12427-bib-0013){ref-type="ref"}, [15](#tca12427-bib-0015){ref-type="ref"}, [19](#tca12427-bib-0019){ref-type="ref"}, [27](#tca12427-bib-0027){ref-type="ref"}, [33](#tca12427-bib-0033){ref-type="ref"} One patient in our study died post‐operatively because of pneumonia and sepsis five months after commencing RT. This patient underwent R1 resection and the pathological report showed ypT2N0. He received 54 Gy RT preoperatively, lung V20 = 28%, lung V10 = 55%, and mean lung dose of 16 Gy, which did not differ from other patients. In the two patients who suffered from grade 4 respiratory failure, one received an RT dose of 64 Gy, lung V20 = 32%, lung V10 = 59%, and mean lung dose of 16 Gy, while the other received an RT dose of 60 Gy, lung V20 = 13%, lung V10 = 50%, and mean lung dose of 12 Gy. A possible explanation for these two respiratory failures may have been the preoperative forced expiratory volume in one second, which has been shown to be independently associated with postoperative pulmonary complications in patients receiving preoperative IMRT, 40--45 Gy, and concurrent chemotherapy followed by thoracic esophagectomy.[19](#tca12427-bib-0019){ref-type="ref"} However, pulmonary function data of these two patients were within normal limits.

Some of the limitations of this study are its retrospective nature, relatively small patient sample, short follow‐up, and selection bias toward more favorable patients in the \>60 Gy group. Cross‐study comparison is, however, limited by the difference in patient characteristics and end point definitions. The risk versus benefit of conducting the study in locally advanced esophageal cancer patients was carefully considered. IMRT provided a higher tumor dose and lower lung dose, which resulted in a higher response rate, improved resection margins, and a low postoperative mortality rate.

In conclusion, our study indicated the efficacy, safety, and feasibility of high dose RT with chemotherapy followed by transthoracic esophagectomy in locally advanced esophageal cancer patients; however, further investigation in a larger prospective randomized controlled trial is required.
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